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Background: In Type 1 diabetes, the insulin-producing β-cells within the pancreatic islets of Langerhans are
destroyed. We showed previously that immunotherapy with Bacillus Calmette-Guerin (BCG) or complete Freund’s
adjuvant (CFA) of non-obese diabetic (NOD) mice can prevent disease process and pancreatic β-cell loss. This was
associated with increased islet Regenerating (Reg) genes expression, and elevated IL-22-producing Th17 T-cells in
the pancreas.
Results: We hypothesized that IL-22 was responsible for the increased Reg gene expression in the pancreas. We
therefore quantified the Reg1, Reg2, and Reg3δ (INGAP) mRNA expression in isolated pre-diabetic NOD islets treated with
IL-22. We measured IL-22, and IL-22 receptor(R)-α mRNA expression in the pancreas and spleen of pre-diabetic and
diabetic NOD mice. Our results showed: 1) Reg1 and Reg2 mRNA abundance to be significantly increased in IL-22-treated
islets in vitro; 2) IL-22 mRNA expression in the pre-diabetic mouse pancreas increased with time following CFA treatment;
3) a reduced expression of IL-22Rα following CFA treatment; 4) a down-regulation in Reg1 and Reg2 mRNA expression in
the pancreas of pre-diabetic mice injected with an IL-22 neutralizing antibody; and 5) an increased islet β-cell DNA
synthesis in vitro in the presence of IL-22.
Conclusions: We conclude that IL-22 may contribute to the regeneration of β-cells by up-regulating Regenerating Reg1
and Reg2 genes in the islets.
Keywords: Adjuvant immunotherapy, Interleukin-22, Regenerating (Reg) genes, Beta-cell regeneration, Type 1 diabetesBackground
Type 1 diabetes (T1D), also known as juvenile diabetes, is
an autoimmune disease characterized by the destruction
of insulin-producing β-cells within the pancreatic islets of
Langerhans. Type 1 diabetes is thought to be caused by a
complex interaction between environmental and genetic
factors that is still not fully understood [1]. This inter-
action causes initial damage to the pancreatic islets leading
to a T-cell mediated autoimmune response that induces
dysregulation and destruction of β-cells via the release of
inflammatory cytokines [2]. Current T1D management* Correspondence: bsingh@uwo.ca
1Department of Microbiology and Immunology, University of Western
Ontario, London, ON, Canada
5Centre for Human Immunology, University of Western Ontario, London, ON,
Canada
Full list of author information is available at the end of the article
© 2013 Hill et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orincludes insulin therapy and pancreas or islet cell trans-
plantation; however, none of these procedures will ensure
the complete removal of diabetic complications. There-
fore, studying the endogenous regeneration of pancreatic
β-cells may suggest strategies for alternative and long-
lasting approaches for T1D management [3].
Endogenous β-cell regeneration is thought to occur ei-
ther by whole islet neogenesis (WIN) via the differentiation
of progenitor cells within the adult pancreas, or by β-cell
replication (BCR) and the regeneration of new β-cells from
pre-existing β-cells [3,4]. Using non-obese diabetic (NOD)
or streptozotocin-injected C57/BL6 mice as a model for
T1D, several groups have shown a possible role for tran-
scription factors, growth factors, and regeneration genes in
stimulating β-cell regeneration. This could result in whole
islet neogenesis (WIN) and subsequent insulin production. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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include pancreatic and duodenal homeobox 1 (PDX-1),
glucagon-like peptide-1 (GLP-1), islet neogenesis-
associated protein (INGAP) and Regenerating protein 1
and 2 (Reg1 and Reg2) [3,5-9]. Recently, platelet-derived
growth factor (PDGF) has also been shown to stimulate β-
cell regeneration via activating cyclin D1 and inducing a
G1 to S transition of the β-cell cycle [10].
Previously, we have shown that a single injection of
Mycobacterium-containing Complete Freund’s Adjuvant
(CFA) into NOD mice has a protective effect against T1D
by down- regulating autoimmunity and restoring normo-
glycemia via the induction of various regulatory T (Treg)
cells [7,11,12]. The role of CFA on endogenous β-cell
replenishment, identified by histological analysis, however,
still remains controversial and the exact mechanism is
presently unknown [5,7].
Several groups have identified the Regeneration gene
family (Reg) as being expressed during the process of
WIN and β-cell regeneration in the pancreas [3,5,7,9,12].
There are seven types of Reg genes present in the mouse
(located on chromosome six with the exception of Reg4)
but only five have been shown to be present in the hu-
man (located on chromosome 2) [13]. The Reg proteins
encoded by these genes are C-type lectins, and have
been found to be also expressed in a variety of tissues
such as the liver, kidney, brain, and gastrointestinal tis-
sues [3,13]. Once secreted, these soluble proteins act in
an autocrine and/or paracrine manner to exert their ef-
fects on their cognate receptors, where they may stimu-
late an anti-microbial, anti-inflammatory, anti-apoptotic,
or regenerative response depending on the tissue type
[3,7,9,13]. In the last decade, Reg1 and Reg3δ (INGAP),
expressed by β-cells and acinar cells respectively, have
been shown to be linked with pancreatic β-cell regener-
ation in the mouse by activating cyclin D1 and promot-
ing β-cell cycle progression [9,13,14]. More recently, we
have shown that Reg2 is substantially up-regulated in the
pancreatic islets, particularly in the β-cells, following ad-
juvant treatment in diabetic and non-diabetic NOD fe-
male mice, as well as in C57BL/6 mice treated with
streptozotocin (STZ). This increased Reg2 expression
has been shown to be associated with an increase in in-
sulin production, a partial reversal of insulitis, and an
improved glucose tolerance test in STZ-treated diabetic
C57BL/6 mice [5]. This led to the conclusion that β-cell
regeneration via up-regulation of the Reg2 gene may
have the capacity to reverse T1D in diabetic mice immu-
nized with CFA using a pathway that is similar to Reg1
and Reg3δ [5,7].
CFA immunization has been shown to induce CD4+
Th17 T cells to produce interleukin IL-17, IL-22, IL-10
and IFN-γ in NOD mice [15]. This finding leads to the
concept that adjuvant-induced cytokines may have thepotential to activate transcription factors that stimulate
Reg proteins such as Reg1, Reg2, and Reg3β (PAP1) [7].
Among these cytokines, IL-22 has been of specific inter-
est because it is released by CD4+ Th17 T cells in dis-
eases such as hepatitis and inflammatory bowel disease,
where IL-22 expression levels have been shown to pro-
mote cell regeneration and survival in hepatocytes and
colonal epithelial cells. Interestingly, IL-22 has also been
found recently to induce Reg gene expression in the pan-
creatic acinar cells surrounding pancreatic islets [16]. IL-
22 is a member of the IL-10 family of cytokines and the
gene is located on human chromosome 12. Like IL-17A
and IL-17F, IL-22 is a glycoprotein, which binds to its
receptor complex (composed of IL-10Rβ and IL-
22Rα) as a homodimer [17,18]. The IL-22 receptor com-
plex is highly expressed in the pancreatic α and β cells
[19]. Upon receptor binding, the tyrosine kinases, JAK
and Tyk1 are phosphorylated which leads to the activa-
tion of the STAT3 transcription factor and subsequent
up-regulation of the Reg genes in the mouse and human
[17,18]. However, the possible induction of the Reg genes
via IL-22 in the pancreatic islets or NOD mouse model
has not yet been examined.
This study sought to test the effects of IL-22 on the regu-
lation of the pancreatic Reg genes, with a focus on Reg2, in
diabetic and pre-diabetic NOD female mice immunized
with CFA. This was accomplished in a two-step process:
Firstly, by studying the direct effect of IL-22 on Reg gene
up-regulation in the NOD mouse pancreatic islets; and
secondly by examining whether CFA immunization could
up-regulate IL-22 expression in the whole pancreas. It was
hypothesized that CFA immunization in pre-diabetic mice
would lead to the production of IL-22 via the induction of
Th17 cells, and that the resulting IL-22 cytokine would ac-
tivate a JAK-STAT3 signal transduction pathway following
binding to its receptor complex on pancreatic β-cells. IL-
22 signaling would then result in the up-regulation of Reg
gene expression that may be linked to β-cell regeneration
and the reversal of hyperglycemia in T1D. This, however,
requires inhibition of autoimmunity to prevent the reversal
of disease. Immunotherapies with mycobacterial adjuvants
such as BCG vaccination have the potential to achieve both
these objectives [20].Results
Recombinant IL-22 up-regulates Reg2 and Reg1 mRNA
expression in the pancreatic islets
To establish whether IL-22 induces Reg gene expression, 6-
week-old pre-diabetic NOD mouse islets were isolated and
incubated with recombinant IL-22 at 10 and 50 ng/mL
concentrations or supernatants from Th17 polarized
splenocytes containing IL-17 and IL-22 [15] (Figure 1).
Quantitative RT-PCR was performed on total extracted
Figure 1 Reg genes and IL-22 receptor (IL-22Rα) expression in
the pancreatic islet cells after IL-22 treatment. Quantitative
RT-PCR analysis was performed using gene-specific primers (Table 1) for
Reg1, Reg2, Reg3δ and IL-22Rα on total RNA isolated from 6-week-old
pancreatic islets (A-D). Islets were harvested 48 hrs after incubation with
either DMEM medium (control); 10, or 50 ng/mL of recombinant IL-22; or
a supernatant of Th17 cells polarized with IL-6 plus IL-23 (2 ml). Results
shown represent the average fold-change in mRNA expression ± SEM
when compared to control-treated islets. N = 3 mice (12 – 14 islets per
mouse). Means indicated by the asterisk (*) are significantly
different (P<0.05).
Hill et al. Cell Regeneration 2013, 2:2 Page 3 of 11
http://www.cellregenerationjournal.com/content/2/1/2RNA from the treated pancreatic islets. Reg2 and Reg1
mRNA levels were found to be significantly higher, by ap-
proximately 3 and 4.2-fold respectively, in islets incubated
with 10 ng/mL of IL-22 when compared to the media con-
trol (P<0.05) (Figure 1A and 1B). Interestingly, the higher
50 ng/mL dose of IL-22 significantly down-regulated Reg2
and Reg1 expression (P<0.05). This was not due to the tox-
icity of the cytokine as there was no change in the viability
of the treated islets cells as compared to media control.
The highest fold increase in Reg2 gene expression was
observed in islets treated with the supernatants of 4 days
culture of BDC2.5 NOD splenocytes conditioned with
IL-23 and IL-6 (Figure 1A). The supernatants also
contained IL-22 and produced a significant 27-fold increase
in Reg2 mRNA abundance when compared to the media
control (P<0.05). Islets treated with the Th17 T cell super-
natant also showed a significant up-regulation of Reg1 gene
expression by approximately 4.3-fold, when compared to
the control islets (P<0.05).However, unlike Reg2, this Reg1
expression was not significantly different when compared
to islets treated with 10 ng/mL of recombinant IL-22. No
significant change in Reg3δ expression was observed in re-
sponse to IL-22 or the Th17 T cell supernatant (Figure 1C).
The effect of recombinant IL-22 and the Th17 cell super-
natant on IL-22 receptor expression was also tested on the
same islet samples using gene-specific primers for the
IL-22 receptor chain, IL-22Rα. As shown in Figure 1D
the mean mRNA levels for IL-22Rα did not increase in is-
lets treated with 10 ng/ml of recombinant IL-22 and in fact
was further reduced with 50 ng/ml of IL-22. Islets treated
with the Th17 cell supernatant induced a significant 2.4-
fold increase in IL-22Rα expression when compared to
control-treated islets (control [1.36±0.21], Th17 T cells
[3.72±0.98], P<0.05).CFA treatment increases the relative mRNA expression for
IL-22 in pancreatic tissue
We have previously shown that CFA injection in non-
diabetic and diabetic NOD mice results in a substantial in-
crease in Reg gene expression [5]. To determine whether
the development of diabetes was accompanied by similar
Figure 2 Expression of IL-22 and IL-22 receptor (IL-22Rα) in the
pancreatic islet cells after CFA immunization. The relative mRNA
expression levels of IL-22 and IL-22Rα (A and B) was carried out in
the pancreas of non-diabetic (4-week old), pre-diabetic (8-week old
and 12-week old), and older (>16 week-old) diabetic NOD mice
following CFA immunization. Female NOD mice were injected i.p.
with either 100 μl of CFA emulsified in saline or with saline alone
and sacrificed 48 hrs following immunization. Whole pancreatic
tissue was homogenized and total RNA extracted for reverse
transcription quantitative real-time PCR analysis using gene-specific
primers. The results shown for each treatment and age group have
been compared to 4-wk-old saline-treated mice and represent the
average fold change of mRNA expression ± SEM. The relative
expression of mRNA was taken from three pooled samples of RNA
per group (with three mice per pooled sample). Age groups
indicated by a double asterisk (**) are significantly different (P<0.05);
treatments indicated by the asterisk (*) are significantly different
from the saline control (P<0.05).
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was performed using IL-22 gene-specific primers for cDNA
using the various NOD mouse treatment/age groups. As
shown in Figure 2A a significant effect of age on IL-22 ex-
pression was detected (F= 6.374; df= 3; P=0.021). Post-hoc
analysis revealed IL-22 mRNA abundance in the pancreas
to be significantly higher in diabetic mice when compared
to non-diabetic (4-week-old) animals (P<0.05). The mean
IL-22 expression tended to be higher in the pre-diabetic (8-
week-old) mice and in diabetic mice following CFA treat-
ment (by approximately 2 and 4-fold respectively).
CFA treatment down-regulates the pancreatic expression
of the IL-22 receptor sub-unit, IL-22Rα
It has previously been reported by Shioya et al. [19] that
the IL-22Rα chain, a member of the IL-22 receptorcomplex, is specifically expressed in the α- and β-cells
within the human pancreas. To determine whether CFA
treatment affected the relative mRNA expression levels of
IL-22Rα in the NOD mouse pancreas, qRT-PCR analysis
was performed using total RNA extracted from non-
diabetic (4-week-old), pre-diabetic (8-week-old and 12-
week-old) and diabetic mice (Figure 2B). A significant
interaction was identified between mouse age and treat-
ment with CFA (F=6.146; df=3; P=0001). When analyzing
the variables separately, CFA treatment was found to sig-
nificantly down-regulate IL-22Rα mRNA expression when
compared to the saline-treated controls for all mouse ages
(F=82.411; df=3; P<0.001) (Figure 2B). IL-22Rα mRNA ex-
pression was also found to significantly alter with age
(F=24.212; df=3; P<0.001). Post-hoc analysis revealed IL-
22Rα mRNA abundance to be significantly higher in dia-
betic mice (P<0.05), when compared to non-diabetic and
pre-diabetic mice. Pre-diabetic mice at 12-weeks of age
were found to have an IL-22Rα mRNA abundance that
was significantly lower (P<0.05), when compared to non-
diabetic (4-week-old), pre-diabetic (8-week-old), and dia-
betic animals.
Reg2 and Reg1 expression is down-regulated in CFA-
treated mice following treatment with an IL-22
neutralizing antibody
To determine whether IL-22 was directly involved in the
up-regulation of Reg expression following CFA treatment,
the abundance of Reg2, Reg1and Reg3δ mRNAs were mea-
sured in the pancreas of 6-week-old NOD mice immu-
nized with CFA followed by i.p injection of an IL-22
neutralizing antibody 1 h later. Mice immunized with CFA
and treated with the IL-22 neutralizing antibody [21] were
found to have a significant reduction (approximately 480-
fold) in Reg2 gene expression when compared to mice im-
munized with CFA and treated with an isotype control
antibody (P<0.001) (Figure 3A). Likewise, Reg1 gene ex-
pression was significantly down-regulated in mice injected
with the IL-22 neutralizing antibody (P<0.001) (Figure 3B).
In contrast, however, no change in Reg3δ expression was
observed for mice immunized with CFA in the presence of
IL-22 neutralizing antibody when compared to mice
injected with the isotype control antibody (Figure 3C).
IL-22 and Reg mRNA expression in the spleen
Since the spleen is a major peripheral lymphoid tissue, we
performed quantitative RT-PCR analysis on splenocytes
derived from 4-week-old, pre-diabetic NOD mice, with or
without CFA treatment, to investigate the presence of
IL-22-producing Th17 cells during autoimmune insulitis
(Figure 4). CFA treatment was found to significantly up-
regulate IL-22 expression in the non-diabetic, 4 week-old
mice by approximately 12-fold (P<0.05). To determine
whether CFA-mediated Reg gene up-regulation occurred
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and Reg3δ mRNA expression was also analyzed in whole
splenic tissue using non-diabetic mice with/without CFA
injection. Similar to Huszarik et al. [5], no effect of treat-
ment was detected on Reg mRNA expression (data
not shown).Figure 3 Expression of Reg genes in the pancreatic islet cells
after IL-22 neutralization. Reg1, Reg2, and Reg3δ gene expression
levels (A-C) was determined in the pancreas of 6-week-old NOD
mice immunized with CFA and treated with an IL-22 neutralizing or
a control antibody. Female NOD mice were injected i.p. with either
100 μl of CFA emulsified in saline followed by 100 μl of IL-22
neutralizing antibody (IL-22-01) 1 hr later, or 100 μl of CFA
emulsified in saline followed by 100 μl of isotype control antibody.
Mice were sacrificed 48 hrs following immunization. Whole
pancreatic tissue was homogenized and total RNA extracted for
reverse transcription quantitative real-time PCR analysis using gene-
specific primers. The results shown for each treatment have been
compared to mice immunized with CFA and the IgG isotype
antibody, and represent the average fold change of mRNA
expression ± SEM. The relative expression of mRNA was taken from
three pooled samples per group (with three mice per pooled
sample). Treatments indicated by the asterisk (*) are significantly
different from the CFA control (P<0.001).CFA treatment does not change Reg or IL-22 mRNA
abundance in the immune-deficient NOD.Scid mouse
pancreas
To verify the finding by Huszarik et al. [5] that Reg up-
regulation following CFA treatment is mediated by an in-
filtrating T cell response, qRT-PCR analysis was performed
on the pancreas of CFA treated non-diabetic (4-week-old)
NOD.Scid mice. NOD-severe combined immune-deficient
(Scid) mice have a deleterious single nucleotide poly-
morphism (SNP) in the Prkdc gene that ultimately affects
T- and B- lymphocyte development. As reported by
Huszarik et al. [5], we found no increase in Reg1, Reg2, or
Reg3δ mRNA abundance in the pancreas of NOD.Scid
mice following CFA treatment (data not shown). This pro-
cedure was repeated using IL-22 gene-specific primers to
confirm that IL-22 was a product of Th17 T lymphocytes,
and was not expressed by the pancreatic cells. As
expected, IL-22 mRNA expression did not change in
CFA-treated NOD.Scid mice (data not shown).IL-22 treatment induces islet β-cell DNA synthesis in vitro
To determine whether IL-22 can promote DNA synthesis
in islet β-cells, we performed immunohistochemical ana-
lysis on isolated islets from 5 to 6-week-old NOD mice
treated with recombinant IL-22 (10 ng/ml) for 48 hours
and stained for nuclear EdU and cytoplasmic insulin
(Figure 5A and B). The percentage of EdU positive β-cells
was found to be significantly higher in islets treated with
recombinant IL-22 when compared to control islets treated
with media alone (P<0.001) (Figure 5C). To confirm resultsFigure 4 Expression of IL-22 in the spleen of 4-week-old
non-diabetic NOD mice following CFA-treatment. The relative
mRNA expression of IL-22 in the spleen of 4-week-old NOD mice
was carried out following CFA-treatment. Quantitative RT-PCR
analysis was performed using gene-specific primers (Table 1) on
total RNA isolated from whole splenic tissue from female NOD mice
injected i.p. with either 100 μl of CFA emulsified in saline or saline
alone. Results shown represent the average fold-change in mRNA
expression ± SEM compared with saline-treated mice. Results were
taken from 3 mice per treatment. The asterisk (*) denotes a
significant difference from the saline control (P<0.05).
Figure 5 Detection of pancreatic islet regeneration after IL-22 treatment. Immunofluorescence localization of nuclear EdU and cytoplasmic
insulin within pancreatic islets was done in 5 to 6-week-old NOD mice. Islets were treated with either DMEM media alone (A) or 10 ng/mL of
recombinant IL-22 for 48 hrs (B) (red = EdU; green = insulin; blue = DAPI). Examples of dual-labeled cells are shown with arrows. The size bar = 50 μm.
(C) The mean percentage ± SEM of β-cells immunopositive for both EdU and insulin relative to insulin alone. Results were taken from 26 control islets
and 46 IL-22-treated islets derived from 4 animals for each group. The asterisk (*) denotes a significant difference from the control (P<0.001). As
described in the Methods section, in parallel experiments we explored the nuclear expression of Ki/67 as a measure of islet cell proliferation (data not
shown). This further confirmed the proliferation of islet cells by IL-22 treatment.
Hill et al. Cell Regeneration 2013, 2:2 Page 6 of 11
http://www.cellregenerationjournal.com/content/2/1/2for DNA synthesis, slides containing IL-22 treated islets
were stained for nuclear Ki/67 protein, which is associ-
ated with cell proliferation. The islets were stained with
mouse anti-Ki/67 followed by incubation with second-
ary antibody. The positive expression of Ki/67 in the is-
lets validated the induction of islet β-cells by IL-22
(data not shown). The ability of IL-22 to increase the
percentage of β-cells undergoing DNA synthesis, as
detected by nuclear labeling with EdU, was inversely re-
lated to islet size (y = −29logx + 56, r2 = 0.31, p<0.001,
n=46). Islet size was estimated from the total number of
insulin-immuno-reactive β-cells present per islet within
tissue sections. No such relationship existed between
islet size and the percent nuclear labeling of β-cells with
EdU for control incubations (y = 2.2logx + 4.3, r2 =
0.01, non-significant, n=26). These findings suggest that
the mitogenic actions of IL-22 on β-cells were greatest
for the smaller islets.Discussion
We have previously shown that immunizing young NOD
mice with CFA can cause regeneration of pancreatic β-
cells by down-regulating autoimmunity and reducing insu-
litis [5,11,12]. However, the cellular mechanisms by which
CFA is able to initiate a regenerative response are not well
understood [7,11]. Recently, CFA treatment in NOD mice
has been shown to substantially up-regulate the regener-
ation gene, Reg2, in pancreatic islets during insulitis, thus
functioning as an important regenerative candidate for β-
cells [5]. The objective of this study was to determine
whether the CFA-induced cytokine, IL-22, was in part re-
sponsible for inducing Reg2 expression and other genefamily members, Reg1 and Reg3δ, leading to a subsequent
increase in β-cell mass and reversal of T1D development.
The exact mechanism underlying CFA-induced Reg gene
upregulation has not been clearly defined. Experiments in
the past have shown IL-6 to be an intermediate for Reg2
and Reg1 gene induction in the pancreas, since the IL-6
upstream response element is conserved among these Reg
genes [5,22]. Since IL-6 signaling leads to the activation of
Stat3 transcription factors inside target cells [23], it was
believed that Reg2 gene induction was also Stat-3 medi-
ated [7]. Our results confirm and extend the role of the
cytokine, IL-22, in up-regulating the Reg2 gene as well as
Reg1, thus supporting our original hypothesis. We con-
firmed a 3-fold and 4.2-fold increase in Reg2 and Reg1
gene expression respectively when pre-diabetic (6-week-
old) pancreatic islets were incubated with 10 ng/mL of re-
combinant IL-22 in vitro for 48 hrs. We have previously
shown that the PCR results for the expression of Reg
genes in the pancreatic islets in our studies correlate with
the expression of Reg proteins by using Western blot assay
[5]. This suggests that Reg2 gene expression, like Reg1, can
be induced via Stat3 signaling and that IL-22 may be an
immune response-mediated agent for the induction of
these Reg genes within the pancreatic islets during insulitis
[7,16] (Figure 6). This finding is supported by a previous
study by Aggarwal et al. [16], who had shown that the
in vivo injection of IL-22 resulted in a rapid induction of
Reg2 expression in the pancreas of C57/BL6 mice. Interest-
ingly, in our in vitro study recombinant IL-22 resulted in a
noticeable down-regulation of Reg2 and Reg1 expression in
the islets from 6-week-old NOD mice when incubated with
high concentrations (50 ng/mL) of IL-22. This may suggest
that pancreatic β-cells exhibit a dose-dependent response
Figure 6 A model for cytokine-mediated up-regulation of the β-cell Reg genes leading to β-cell regeneration. Interleukin-22 (red) binds
to its receptor complex, IL-22Rα/IL-10Rβ, which activates the Stat3 transcription factor protein (1), STAT3 then migrates into the nucleus of the
β-cell and stimulates Reg gene transcription and translation (green). Secreted Reg proteins are then thought to activate Cyclin D1. This allows the
β-cell to enter the G1/S transition of the cell cycle leading to regeneration. IL-22 can also activate the MAP3 kinases leading to Cyclin D1 (2),
which in turn inactivates the Retinoblastoma (Rb). Platelet-derived growth factor (PDGF) (blue) similarly leads the activation of Cyclin D1, which in
turn inactivates Rb allowing the release of sequestered transcription factors (TF) essential for the G1–S progression of the cell cycle. Reg2 gene
expression by activating Stat3, believed to be caused by receptor-induced Src kinase activity. The known signaling pathways (black and blue) and
the proposed signaling pathways (green) are identified.
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tory to islet Reg gene expression. In contrast to the other
Reg genes, the expression of Reg3δ was not affected by
IL-22 treatment in the pancreatic islets and thus confirms
past studies showing Reg3δ expression to be absent in the
α- and β-cells. We also found Reg2 and Reg1 expression to
be drastically reduced in the pancreas of pre-diabetic mice
injected with a neutralizing IL-22 antibody, confirming that
IL-22 is an upstream activator for these Reg genes. These
findings support the study by Zhang et al. [24] who found
the Reg1 and Reg2 genes to be induced by IL-22 in the co-
lonic epithelial cells of Citrobacter rodentium-infected WT
mice, but for expression to be completely abolished in
IL-22 knock-out infected mice. As shown by our studies
with Th17 supernatant, cytokines other than IL-22 may
contribute to the upregulation of Reg genes. We are cur-
rently exploring this possibility in our laboratory.
Using the whole pancreas from NOD mice, Huszarik
et al. [5] found several members of the Reg gene family
to be up-regulated with age, and Reg2 to be further
upregulated in diabetic mice following CFA treatment.
Our results support the finding that Reg2 plays a dominant
role in endogenous β-cell regeneration following adjuvant
immunotherapy. Reg2 mRNA levels were found to grad-
ually increase in pre-diabetic mice with age and were in-
creased in diabetic mice following CFA immunization [5].
Similar to Reg2, IL-22 gene expression gradually increasedwith pre-diabetic age and was also increased following
CFA treatment in both pre-diabetes and following the on-
set of diabetes. The similar pattern of expression between
Reg2 and IL-22 after CFA treatment further suggests Reg2
to be a gene target in the IL-22 signaling pathway. How-
ever, unlike IL-22, the expression of its receptor chain, IL-
22Rα, unexpectedly dropped at all ages following CFA
treatment. In a study analyzing mantle cell lymphoma
growth caused by IL-22, Gelebart et al. [25] discovered
that the gene promoter for IL-22Rα contained multiple
binding sites for NF-κB, a transcription factor that when
activated contributes to the pathogenesis and progressive
loss of pancreatic β-cells by generating reactive oxygen
species and promoting β-cell apoptosis. It is therefore pos-
sible that the effects of CFA may lead to the disruption or
degradation of NF-κB that would in turn reduce/prevent
IL-22Rα. Whether CFA affects the integrity of NF-κB,
however, would require further investigation. Alterna-
tively, IL-22 binding protein (IL-22BP) may increase in cir-
culation with age and inhibit the expression of IL-22
receptor in pancreas.
In the spleen, we found Reg mRNA levels to be absent,
thus supporting the finding by Huszarik et al. [5] that
the Reg genes are pancreas-specific with/without CFA
treatment. In contrast to Reg2 expression, however, the
IL-22 mRNA levels in splenocytes were found to be in-
creased in non-diabetic (4-week-old) NOD mice
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Nikoopour et al. [15] that IL-22 is a secretory product
induced by CFA.
We have identified IL-22 as a Reg gene inducer in the
NOD mouse pancreatic islets. Reg proteins act as auto-
crine/paracrine growth factor for pancreatic β-cell regen-
eration. They increase ATF-2 that binds to the cyclin D1
gene and leads to signaling pathway to induce β-cell re-
generation [26]. It is also important to note, however, that
like PDGF [10] and Reg1[9,13], IL-22 has been shown by
Radaeva et al. [27] to be directly involved in promoting
cell cycle progression and cell survival. Using in vitro
treatment of recombinant IL-22 at a concentration similar
to our own study of 10 ng/mL, Radaeva et al. [27] were
able to promote cell growth and survival of human hepa-
tocellular carcinoma HepG2 cells via the activation of a
series of anti-apoptotic and mitogenic proteins which in-
cluded: Bcl-2, Bcl-xL, Mcl-1, c-myc, and cyclin D1. Due to
the ontological similarity between hepatic cells and pan-
creatic cells, we also investigated the effect of IL-22 on
pancreatic islet cell growth. We found increased DNA
synthesis in the IL-22 treated islets. The extent to which
this increase was dependent on the production of Reg2 or
Reg1 by these islets, however, will require further investi-
gation. The mitogenic effect of IL-22 was greater on the
smaller-sized islets, suggesting that this population of β-
cells may have a greater regenerative capacity. Smukler
et al. [28] reported a sub-population of insulin-expressing
β-cells located in small islets in both the mouse and hu-
man pancreas that had a high mitogenic potential, but did
not express the glucose transporter-2. These cells were
shown to be lineage multipotent and capable of forming
multiple islet endocrine cell types, as well as neural cells,
and may represent a β-cell progenitor population that can
contribute to islet regeneration.
CFA-treated diabetic NOD mice have been previously
shown to partially reverse T1D by down-regulating
autoimmunity and stimulating endogenous β-cell regen-
eration through a mechanism that is presently un-
known. This regeneration process, however, is not
enough to prevent the disease entirely, as newly
regenerated β-cells are still selectively destroyed by on-
going autoimmunity, but is believed to involve the mito-
genic Reg gene family. We have demonstrated that the
cytokine, IL-22, can up-regulate Reg2 and Reg1 expres-
sion when directly co-cultured with pre-diabetic pan-
creatic islets in vitro. Thus, IL-22 represents a newly
discovered mediator for up-regulating islet Reg expres-
sion using a JAK/STAT3 signal transduction pathway.
We have also shown that excess IL-22 may have an in-
hibitory effect on islet Reg expression, that the mRNA
levels for IL-22 are up-regulated with increasing age
and development of disease in the NOD mouse, that
CFA treatment causes a down-regulation of the IL-22Rαreceptor chain, and that IL-22 can increase β-cell DNA
synthesis when directly applied to pancreatic islets
in vitro.
In conclusion, this study has identified the cytokine,
IL-22, to be involved in up-regulating Reg2 and Reg1
gene family members and increasing β-cell DNA synthe-
sis within pancreatic islets. This could result in β-cell re-
generation in islets and that could potentially be
incorporated into future therapeutic strategies for dis-
ease management in Type 1 diabetes.Methods
Animals
Female NOD/Ltj mice at 4, 8 and 12 weeks of age, and
diabetic NOD mice, shortly after the diagnosis of diabetes
(blood glucose greater than 11 mM and polyuria), as well
as NOD.SCID mice at 4 weeks or as adults, were obtained
from the University of Western Ontario, London, Ontario,
Canada and housed in a pathogen-free environment. Mice
were housed three per cage, with food and water provided
ad libitum, and maintained on a 12-hour light/dark cycle.
Blood glucose was measured from a tail sample using a
glucometer (Bayer, Elkhart, IN). All experiments followed
the Canadian Council for Animal Care guidelines
and were approved by the Animal Use Sub-Committee,
University of Western Ontario.
Treatments
Complete Freund’s adjuvant (CFA) was purchased from
Sigma Aldrich (St. Louis, MO). To determine the effect of
CFA on Reg2, Reg1, Reg3δ, IL-22, and IL-22-receptor(R)-α
expression, mice were injected i.p. either with 100 μl of
CFA (50 μg/mL) emulsified in saline (1:1), or with 100 μl of
saline alone for control in 4, 8, 12-week, and diabetic NOD
mice. To determine the effect of IL-22 neutralization on
Reg expression; three 5 to 6 week-old NOD mice were
injected i.p. with 100 μl of CFA with saline (1:1) followed
1 hr later with 100 μl (i.p.) of 3 mg/mL rat anti-mouse
IL22-01 monoclonal antibody (21) or isotype matched con-
trol antibody (Pfizer). Mice were sacrificed in a CO2 cham-
ber 48 hrs later for tissue extraction.
Extraction of splenocytes and pancreas
Approximately 50 mg of whole spleen or pancreatic tissue
from NOD/Ltj and NOD.SCID mice was homogenized in
a solution containing buffer RLT (Qiagen, Mississauga,
ON) and 2-Mercaptoethanol (Sigma Aldrich, St. Louis,
MO) using a PowerGen 700 homogenizer (Fisher Scien-
tific, Pittsburgh, PL).
Isolation of pancreatic islets
NOD mice were sacrificed by cervical dislocation. Cold
collagenase XI (0.23 mg/mL, Sigma Aldrich, St. Louis,
Table 1 List of genes and primer sequences used for qRT-PCR
Gene symbol Forward primer (5’→3’) Reverse primer (5’→3’) Product size (bp)
Reg2 cactgccaaccgtggttat gacaaaggagtactgtgcctca 75
Reg1 catctgccaggatcagttgc aggtaccataggacag 549
Reg3δ (INGAP) ccatggtgtctcacaagacc tgatgcgtggagaagacagt 117
IL-22 tcagctcagctcctgtcacat tccccaatcgccttgatctct 117
IL-22Rα gctcgctgcagcacactacca tctgtgtcgggagtcaggcca 247
β-actin gcccagagcaagagaggtat cacacgcagctcattgtaga 116
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common bile duct. Collagenase at 37°C was used to digest
the pancreatic tissue. Connective tissues and remaining
cells were removed using Hank’s buffered salt solution
(HBSS) (Invitrogen, Carlsbad, CA) containing 5% (v/v) fetal
calf serum (FCS) (HyClone Laboratories, Logan, UT). Islet
separation was accomplished by density gradient centrifu-
gation using dextran (Sigma Aldrich, St. Louis, MO). Cells
located at the interface of dextran gradient layers of 11%
and 23% were harvested by pipette and washed in Roswell
Park Memorial Institute (RPMI) 1640. Individual pancre-
atic islets were handpicked and cultured in Dulbecco’s
modified eagle medium (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 100 U/mL streptomycin (GIBCO,
Grand Island, NY), 5 μg/mL penicillin, and 10% (v/v) FCS
at 37°C.Culture of pancreatic islets cells with IL-22
Pancreatic islets were isolated from young (4–6 wk old)
NOD mice. They were equilibrated overnight at 37°C,
5% CO2 in RPMI-1640 medium supplemented with 10%
fetal calf serum (FCS), 100 U/mL streptomycin and
5 μg/mL penicillin and islets were handpicked and dis-
tributed into 24 well plate (~50 islets per well) and
treated with recombinant mouse IL-22 (10 ng/ml or
50 ng/ml, R&D systems, Minneapolis, MN) or with 2 ml
of Th17-cell supernatant from IL-6/IL-23 treated
splenocytes [15]. Two days later, islets were harvested
for RNA extraction.RNA extraction
Total RNA from isolated splenocytes, pancreatic or islet
cells was extracted from homogenates using an RNeasy
Midi Kit (Qiagen, Mississauga, ON). A DNase 1 treatment
kit (Ambion, Austin, TX) was used to eliminate DNA con-
tamination. The RNA content was quantified by measuring
absorbance at 260 nm using a Nanodrop 1000 spectropho-
tometer (NanoDrop Products, Wilington, DL), and the in-
tegrity of selected RNA samples was checked using agarose
gel electrophoresis and ethidium bromide to identify the
presence of the 18S and 28S rRNA bands.Real time polymerase chain reaction
Approximately 1 to 5 μg of total RNA was taken from
each sample and reverse transcribed into cDNA using
oligo dT12-18 primers from Superscript III first-strand
Synthesis SuperMix for quantitative RT-PCR (Invitrogen,
St. Louis, MO). The cDNA concentration was measured
using a spectrophotometer and was diluted to 225 ng/μL
in diethyl pyrocarbonate water and amplified by
PCR using a Quantifast SYBR Green PCR Kit (Qiagen,
Mississauga, ON) with specific primers for Reg1, Reg2,
Reg3δ, IL-22 and IL-22Rα1.25 μL) (Table 1). DNA was
amplified by PCR in a two-step melting/annealing pro-
gram for up to 40 cycles using a Corbett Rotor-Gene 6000
thermocycler (Corbett Life Sciences, San Francisco, CA).
This thermocycler program consisted of preheating the
samples at 95°C for 5 min, cycling at 95°C for 10 sec and
60°C for 20 sec, and a melting phase of 60 to 95°C. β-actin
was used as the housekeeping gene for relative quantifica-
tion. The efficiency of each set of primers was determined
by the standard curve method.
Fluorescence immunohistochemistry for detection of
β-cell DNA synthesis
Approximately 50 isolated islets from 5 to 6 week-old
NOD mice were added to four wells of a six well tissue cul-
ture plate and treated either with 10 ng/mL of recombin-
ant IL-22 as above in DMEM media, or in DMEM media
alone as a control, for 48 hrs. Islets were fixed in 4% para-
formaldehyde (PFA) for 1 hr at 4°C and re-suspended in
2% low melting point (LMP) Agarose (Fisher Scientific)
which was first liquefied by heating to 80°C. The islets em-
bedded in Agarose were dehydrated in 70% ethanol and
embedded in paraffin. Sections of 5 μm were cut and
mounted on glass slides. EdU staining was performed using
a Click-it EdU cell proliferation kit (Invitrogen) according
to the manufacturer’s instructions. Non-specific staining
was blocked using Background Sniper (Biocare Medical,
Concord, CA, U.S.A.) for 10 min, and the sections incu-
bated overnight with the primary antibody, mouse anti-
insulin (1:2000; Sigma Aldrich, St. Louis, MO) followed by
a 1 h incubation with secondary antibody, Alexafluor 488
goat anti-mouse (1:500; Invitrogen). Cells were co-stained
with nuclear DAPI (1:500; Sigma Aldrich, St. Louis, MO).
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fied and analyzed, and the percentage of EdU-positive β-
cells was quantified. To confirm results for DNA synthesis,
slides containing sections from 15 additional islets were
stained for nuclear Ki/67 overnight using the primary anti-
body, mouse anti-Ki/67 (1:2000; Sigma Aldrich), followed
by a 1 h incubation with secondary antibody, Alexafluor
555 goat anti-mouse (1:500; Invitrogen). Analysis of the
islet sections was performed by fluorescence microscopy
and the images were analyzed using Northern Eclipse
Version 7.0 software (Empix Imaging, Inc., Mississauga,
ON, Canada).Statistical analysis
Normally distributed data were analyzed with SPSS statis-
tical software using a one-way or two-way ANOVA, and
significant changes between variables were detected using
a Tukey’s test. The α value was set to 0.05.
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